nadp has been researched along with Fatty Liver, Nonalcoholic in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, M; Huang, Y; Ji, J; Niu, X | 1 |
| Kryl'skii, ED; Kuptsova, GN; Pashkov, AN; Popov, SS; Popova, TN; Raskina, EA; Shulgin, KK | 1 |
| Fu, Z; Ibrahim, AS; Kim, H; Liu, W; Qi, NR; Shamsa, EH; Song, Z; Sun, S; Yang, Z; Yumnamcha, T; Zhang, K; Zhang, R | 1 |
| Becerra, MCS; Camarillo, CO; Cruz, M; Flores, MD; Gutman, LAB; Mejía, SÁ; Navarro, RM; Pérez, EH; Santana, LD | 1 |
| Ahn, S; Jeon, MJ; Kim, H; Kim, OH; Lee, C; Lee, Y; Oh, BC; Yu, U | 1 |
| Guo, L; Zhang, C | 1 |
6 other study(ies) available for nadp and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Liraglutide inhibits receptor for advanced glycation end products (RAGE)/reduced form of nicotinamide-adenine dinucleotide phosphate (NAPDH) signaling to ameliorate non-alcoholic fatty liver disease (NAFLD) in vivo and vitro.
Topics: Animals; Hydrogen Peroxide; Liraglutide; Liver; Mice; NADP; NADPH Oxidase 2; Non-alcoholic Fatty Liver Disease; Reactive Oxygen Species; Receptor for Advanced Glycation End Products; Tumor Necrosis Factor-alpha | 2022 |
Inflammation is associated with impairment of oxidative status, carbohydrate and lipid metabolism in type 2 diabetes complicated by non-alcoholic fatty liver disease.
Topics: Antioxidants; Blood Glucose; Case-Control Studies; Cholesterol; Diabetes Mellitus, Type 2; Glutathione; Humans; Inflammation; Insulin Resistance; Lipid Metabolism; Lipids; NADP; NF-kappa B; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Tumor Necrosis Factor-alpha | 2022 |
The mitochondrial NAD kinase functions as a major metabolic regulator upon increased energy demand.
Topics: Animals; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Humans; Liver Neoplasms; Mice; Mice, Knockout; Mitochondria; Mitochondrial Proteins; NAD; NADP; Non-alcoholic Fatty Liver Disease; Phosphotransferases (Alcohol Group Acceptor) | 2022 |
Nicotinamide prevents sweet beverage-induced hepatic steatosis in rats by regulating the G6PD, NADPH/NADP
Topics: Animals; Beverages; Fructose; Gene Expression Regulation, Enzymologic; Glucose; Glucosephosphate Dehydrogenase; Glutathione Disulfide; Liver; Male; NADP; NADPH Oxidase 4; Niacinamide; Non-alcoholic Fatty Liver Disease; Oxidation-Reduction; Oxidative Stress; Rats; Rats, Sprague-Dawley; RNA, Messenger; Thiobarbituric Acid Reactive Substances; Tumor Necrosis Factor-alpha | 2018 |
High resolution in vivo 31P-MRS of the liver: potential advantages in the assessment of non-alcoholic fatty liver disease.
Topics: Animals; Disease Models, Animal; Ethanolamines; Glycerylphosphorylcholine; Liver Cirrhosis; Magnetic Resonance Spectroscopy; Male; NADP; Non-alcoholic Fatty Liver Disease; Phosphatidylethanolamines; Phosphorus; Phosphorylcholine; Rats; Rats, Sprague-Dawley | 2015 |
[Interaction of polymorphisms of monocyte chemoattractant protein-1 receptor CCR2 gene 190A/G, nicotinamide adenine dinucleotide phosphate oxidase subunit p22phox gene C242T and cigarette smoking increases the risk of nonalcoholic fatty liver disease].
Topics: Chemokine CCL2; Genotype; Humans; NADP; NADPH Oxidases; Nicotiana; Non-alcoholic Fatty Liver Disease; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Receptors, CCR2; Risk; Risk Factors; Smoking | 2015 |